{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"1.930","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"720,160,912","primaryexch":"香港交易所","ric":"2137.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BND89B5","am":"9.83","iv":"","ew_strike":"","as":"1.880","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"1.870","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"0.800","shares_issued_date":"2025年9月22日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"Zhi Hong","underlying_ric":"2137.HK","hi52":"3.090","issuer_name":"騰盛博藥生物科技有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"1.860","mkt_cap":"1.34","f_aum_hkd":null,"ew_sub_per_to":"","ls":"1.870","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.060","aum":"","issued_shares_class_B":null,"vo":"5.25","secondary_listing_flag":false,"listing_date":"2021年7月13日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"騰盛博藥生物科技有限公司 - B","nm_s":"騰盛博藥－Ｂ","sym":"2137","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"騰盛博藥生物科技有限公司是一家主要專注於開發感染性疾病及中樞神經系統疾病治療方案的生物技術公司。該公司的HBV產品組合包括專有的治療性疫苗BRII-179、the siRNA BRII-835 (elebsiran)，及中和抗體BRII-877 (tobevibart). 該公司擁有多種創新候選藥物的產品線，專注於治療傳染病和中樞神經系統疾病。該公司的產品應用於傳染病（如乙型肝炎病毒(HBV)、人類免疫缺陷病毒(HIV)、多重耐藥(MDR)或廣泛耐藥性(XDR)革蘭氏陰性菌感染）及其他疾病（如中樞神經系統(CNS)疾病）。該公司主要在中國國內市場開展業務。","op":"1.930","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港銅鑼灣<br/>希慎道33號<br/>利園一期<br/>19樓1920室","pc":"-3.11","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"1.930","isin":"KYG1645A1094","moneyness":""}},"qid":"1759074383485"}
